FDA ALERT [08/2009]: As announced on April 30, 2009, based on a safety evaluation of the botulinum toxin products, FDA has concluded that the prescribing information for OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic) and RimabotulinumtoxinB (marketed as Myobloc) must be updated to ensure their continued safe use.  On July 31, 2009, FDA, under the authorities granted by the Food and Drug Administration Amendments Act (FDAAA) of 2007, approved the following revisions to the prescribing information of Botox/Botox Cosmetic and Myobloc:

 The other botulinum toxin product in this class, AbobotulinumtoxinA (marketed as Dysport), was approved on April 29, 2009 and included the Boxed Warning, REMS, and new established name at the time of approval.

The following table lists the established name changes and the approved indications for each product. The marketed trade names and the product formulations have not changed for these products.

Summary of FDA-Approved Botulinum Toxin Products

Trade Name*

NEW Drug Name

OLD Drug Name

Indication

Botox OnabotulinumtoxinA Botulinum toxin type A Cervical dystonia, Severe primary axillary hyperhidrosis, Strabismus, Blepharospasm
Botox Cosmetic OnabotulinumtoxinA Botulinum toxin type A Temporary improvement in the appearance of moderate to severe glabellar lines
Dysport AbobotulinumtoxinA Botulinum toxin type A Cervical dystonia, Temporary improvement in the appearance to moderate to severe glabellar lines
Myobloc RimabotulinumtoxinB Botulinum toxin type B Cervical dystonia
* The marketed trade names and the product formulations have not changed. 

Considerations for Health Care Professionals

Information for patients, family members, and caregivers:

The FDA urges both healthcare professionals and patients to report side effects from the use of botulinum toxin products to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.

Contact FDA